The NOD audit: Insights into the current state of management for neovascular age-related macular degeneration.
作者信息
Teo Kelvin Yi Chong
机构信息
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.
Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.
出版信息
Eye (Lond). 2023 Dec;37(17):3521-3522. doi: 10.1038/s41433-023-02546-4. Epub 2023 May 4.
Abstract
摘要
相似文献
1
The NOD audit: Insights into the current state of management for neovascular age-related macular degeneration.
Eye (Lond). 2023 Dec;37(17):3521-3522. doi: 10.1038/s41433-023-02546-4. Epub 2023 May 4.
2
The Therapeutic Conversation and a Holistic Approach to the Management of Patients with Neovascular Age-Related Macular Degeneration.
Ophthalmologica. 2022;245(4):393-394. doi: 10.1159/000524761. Epub 2022 Apr 27.
3
Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it?
Retina. 2020 Aug;40(8):1451-1455. doi: 10.1097/IAE.0000000000002870.
4
OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
Retina. 2020 May;40(5):881-890. doi: 10.1097/IAE.0000000000002470.
5
Double-layer sign in neovascular age-related macular degeneration - do we treat?
Acta Ophthalmol. 2022 May;100(3):348-349. doi: 10.1111/aos.14944. Epub 2021 Jun 16.
6
Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
Retina. 2015 May;35(5):966-74. doi: 10.1097/IAE.0000000000000460.
7
Interleukin levels in neovascular age-related macular degeneration: evaluation of morphological and functional progression over 5 years.
Graefes Arch Clin Exp Ophthalmol. 2022 Oct;260(10):3397-3399. doi: 10.1007/s00417-022-05635-4. Epub 2022 Apr 12.
8
Swept-source optical coherence tomography angiography features of sub-retinal fibrosis in neovascular age-related macular degeneration.
Clin Exp Ophthalmol. 2019 Mar;47(2):233-239. doi: 10.1111/ceo.13367. Epub 2018 Nov 13.
9
Choroidal cleft simulating choroidal caverns in neovascular age-related macular degeneration.
Eur J Ophthalmol. 2019 Sep;29(5):471-473. doi: 10.1177/1120672119855540. Epub 2019 Jul 29.
10
Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Eur J Ophthalmol. 2020 Sep;30(5):1082-1090. doi: 10.1177/1120672119848961. Epub 2019 May 14.
本文引用的文献
1
The Royal College of Ophthalmologists Commissioning guidelines on age macular degeneration: executive summary.
Eye (Lond). 2022 Nov;36(11):2078-2083. doi: 10.1038/s41433-022-02095-2. Epub 2022 May 27.
2
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study.
Br J Ophthalmol. 2016 Dec;100(12):1623-1628. doi: 10.1136/bjophthalmol-2015-308166. Epub 2016 Mar 30.
3
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Br J Ophthalmol. 2015 Feb;99(2):220-6. doi: 10.1136/bjophthalmol-2014-305327. Epub 2014 Sep 5.
4
Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.
Retina. 2013 Mar;33(3):474-81. doi: 10.1097/IAE.0b013e31827b6324.
5
Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
Acta Ophthalmol. 2013 Sep;91(6):540-6. doi: 10.1111/j.1755-3768.2012.02493.x. Epub 2012 Nov 22.
6
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17.
7
One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study.
J Ophthalmol. 2011;2011:405724. doi: 10.1155/2011/405724. Epub 2011 Nov 28.
8
Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Am J Ophthalmol. 2009 Sep;148(3):409-13. doi: 10.1016/j.ajo.2009.04.001. Epub 2009 May 24.
9
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med. 2006 Oct 5;355(14):1432-44. doi: 10.1056/NEJMoa062655.
10
Ranibizumab for neovascular age-related macular degeneration.
N Engl J Med. 2006 Oct 5;355(14):1419-31. doi: 10.1056/NEJMoa054481.
Zotero 插件